Compare Cenovus Energy Inc (CVE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Novo Nordisk A/S — how do they compare? Cenovus Energy Inc trades at $30.22 (market cap $55.00B), while Novo Nordisk A/S trades at $46.23 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 3.8× Cenovus Energy Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| CVE | NVO | |
|---|---|---|
Market Cap | $55.00B | $207.85B |
Sector | Energy | Health |
52-Week High | $31.80 | $63.98 |
52-Week Low | $14.83 | $35.29 |
Enterprise Value | $61.08B | $222.55B |
Dividend Yield | 2.09% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $29.56, up 4.64% with bullish technical momentum. The stock shows strong fundamentals with attractive valuation ratios (P/E 11.56, EV/EBITDA 5.77) and solid profitability (ROE 20.96%). Recent Q2 2026 earnings matched estimates with record oil sands production driving operational strength. Analyst consensus leans positive with 40.7% buy ratings despite mixed quarterly performance.
CVE presents value opportunity with robust cash flow generation and production growth, though faces commodity price volatility risks. Wall Street sentiment remains cautiously optimistic with institutional accumulation supporting upside potential. Key risks include oil price dependency and refining margin pressures that could impact earnings stability.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
